Stephen Oh, MD, PhD

Hematologist

Stephen Oh

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Stephen Oh, MD, PhD

Watch video on YouTube

Stephen Oh, MD, PhD

5 mins

Dr. Stephen Oh, Associate Professor of Medicine and Pathology and Immunology at Siteman Cancer Center, explains what drew him into medicine, specifically hematology.

Clinical Expertise

  • Myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia, chronic myelomonocytic leukemia, systemic mastocytosis, hypereosinophilic syndrome

Primary Academic Title

Professor of Medicine and Pathology and Immunology, Co-Chief, Division of Hematology, WashU Medicine

Board Certification

  • 2007: American Board of Internal Medicine, Internal Medicine
  • 2010: American Board of Internal Medicine, Hematology

Training

  • 2004 - 2006: Resident, Internal Medicine, Stanford University, Stanford, CA
  • 2006 - 2010: Fellow, Hematology/Oncology, Stanford University, Stanford, CA

Education

  • 2002: PhD, Northwestern University, Chicago, IL
  • 2004: MD, Northwestern University, Chicago, IL

Research & Selected Publications

Research Interest

Pathogenesis of myeloproliferative neoplasms (MPNs), the initiation, development, and progression of MPNs, utilizing patient samples and animal models to interrogate dysregulated cytokine-signaling networks in MPNs

Research Publications

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelo…
Authors:

Palandri F, Schaap NPM, Rey J, one or more additional authors omitted Oh ST

Journal & Year:

Clin Lymphoma Myeloma Leuk | 2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Oh ST, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun | 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Authors:

Pilcher WC, Yao L, Gonzalez-Kozlova E, one or more additional authors omitted Oh ST, one or more additional authors omitted Bhasin M

Journal & Year:

Nat Cancer | 2026

A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies
Authors:

He F, Lin S, Gao B, one or more additional authors omitted Oh ST

Journal & Year:

Cell Commun Signal | 2025

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase…
Authors:

Mesa R, Gill H, Zhang L, one or more additional authors omitted Oh ST, one or more additional authors omitted Masarova L

Journal & Year:

Lancet Haematol | 2025

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Authors:

Rampal RK, Grosicki S, Chraniuk D, one or more additional authors omitted Oh ST, one or more additional authors omitted Mascarenhas J

Journal & Year:

Nat Med | 2025

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib
Authors:

Harrison CN, Mesa R, Talpaz M, one or more additional authors omitted Oh ST

Journal & Year:

Clin Lymphoma Myeloma Leuk | 2025

RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia
Authors:

Kong T, Laranjeira ABA, Letson CT, one or more additional authors omitted Oh ST

Journal & Year:

Nat Commun | 2025